RxDoctor Payments DataLook up a doctor →

Sujith Kalmadi, MD

Hematology & Oncology · Chandler, AZNPI 1508973447

Payments from drug & device makers

$4,719,547in general payments, 2019–2025

Across 2,871 payments — averaging $1643.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$842K
  • Pfizer$757K
  • Daiichi Sankyo Inc.$568K
  • AstraZeneca$529K
  • Genentech, Inc.$320K
  • Cornerstone Specialty Network LLC$193K
  • plus $1.5M from 54 others
$2,210in research payments, 2019–2025

Across 3 payments — averaging $736.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited8$841,856
Pfizer217$757,086
Daiichi Sankyo Inc.165$567,568
AstraZeneca(2 entities)208$529,224
Genentech, Inc.47$319,543
Cornerstone Specialty Network LLC36$193,260
Bayer100$186,952
Johnson & Johnson(2 entities)254$160,349
Novocure Inc.46$111,268
Genentech USA, Inc.136$105,587
Seagen Inc.61$102,574
Takeda Pharmaceuticals U.S.A., Inc.65$89,363
G1 Therapeutics, Inc.64$79,802
AbbVie61$79,674
Incyte Corporation84$61,230
Pharmacyclics LLC, An Abbvie Company110$61,192
E.r. Squibb & Sons, L.L.C.178$50,550
Beigene USA, Inc.60$47,669
Amgen62$39,145
Veru Inc.10$36,614
Lilly USA, LLC26$27,396
Karyopharm Therapeutics Inc.16$27,323
Mirati Therapeutics, Inc.20$26,842
Novartis155$23,695
Blueprint Medicines Corporation28$22,278
Jazz Pharmaceuticals Inc.14$15,809
Beone Medicines USA, Inc.15$15,252
EMD Serono, Inc.20$10,808
Eli Lilly7$10,477
Astellas Pharma US Inc14$10,147
Sanofi30$8,987
Genmab U.S., Inc.19$8,891
Bristol Myers Squibb66$8,786
Tesaro, Inc.9$6,269
Epizyme, Inc.12$6,259
Gilead(2 entities)54$5,877
Taiho Oncology, Inc.8$5,814
Merck65$5,413
Ipsen Biopharmaceuticals, Inc13$5,357
Regeneron12$4,973
Janssen Scientific Affairs, LLC3$4,320
Rigel Pharmaceuticals, Inc.19$3,977
Angiodynamics, Inc.2$3,750
Spectrum Pharmaceuticals Inc.13$3,289
Athenex Pharmaceutical Division, LLC4$3,075
Eisai Inc.26$2,946
Onmark, Inc.11$2,933
Puma Biotechnology, Inc.19$2,876
Regeneron Healthcare Solutions, Inc.26$2,501
Deciphera Pharmaceuticals Inc.1$2,500
Astellas Pharma Global Development1$1,743
Coherus Oncology, Inc.2$1,372
Exelixis Inc.11$1,339
Geron Corporation2$1,233
GSK34$1,089
Macrogenics, Inc.2$425
Covis Pharma GmbH2$400
Array Biopharma Inc24$377
Caris MPI, Inc.1$220
ADC Therapeutics America, Inc.9$189

How this compares

$4,719,547 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona →

Medicare billing

Part B allowed, 2024
$6,011,831
Medicare patients
833
Services billed
305,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Chandler

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →